Tacrine
Tacrine is a cholinesterase inhibitor that was used as a medication for the treatment of Alzheimer's disease. It was the first drug approved by the Food and Drug Administration (FDA) for this purpose. Tacrine is known by its brand name, Cognex.
History[edit]
Tacrine was first synthesized in the 1940s and was initially investigated for its potential use in treating myasthenia gravis. However, it was not until the 1980s that its potential for treating Alzheimer's disease was explored. In 1993, Tacrine became the first drug approved by the FDA for the treatment of Alzheimer's disease.
Mechanism of Action[edit]
Tacrine works by inhibiting the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By preventing the breakdown of acetylcholine, Tacrine increases the levels of this neurotransmitter in the brain, which is thought to help alleviate some of the symptoms of Alzheimer's disease.
Pharmacokinetics[edit]
Tacrine is administered orally and is rapidly absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, primarily by the enzyme cytochrome P450 1A2 (CYP1A2). The drug has a relatively short half-life, necessitating multiple doses throughout the day to maintain therapeutic levels.
Side Effects[edit]
The use of Tacrine is associated with several side effects, the most common of which are gastrointestinal disturbances such as nausea, vomiting, and diarrhea. More serious side effects include hepatotoxicity, which has limited its use. Regular monitoring of liver function tests is required for patients on Tacrine therapy.
Discontinuation[edit]
Due to its side effects and the development of newer cholinesterase inhibitors with better safety profiles, Tacrine has largely fallen out of favor and is no longer widely used. Other drugs such as donepezil, rivastigmine, and galantamine have largely replaced Tacrine in the treatment of Alzheimer's disease.
See Also[edit]
References[edit]
External Links[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian